永安药业: 股票交易异常波动公告

Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative increase exceeding 20% over two consecutive trading days on May 14 and May 15, 2025 [1][2] - The board of directors confirmed that there are no undisclosed significant matters related to the company, and the recent operational situation remains normal without major changes in the internal and external business environment [2] - The company has not identified any undisclosed information that could significantly impact its stock price, and previous disclosures do not require correction or supplementation [2][3] Group 2 - The company is closely monitoring the situation regarding its actual controller and chairman being detained, and will fulfill its information disclosure obligations as required [1][2] - The board of directors emphasized that there are no violations of fair information disclosure, and all information should be verified through designated media [2]